A systematic review published in Alzheimer’s Research & Therapy has examined the growing landscape of commercially available digital cognitive-oriented therapies for individuals living with mild cognitive impairment or dementia. The study, led by Francesco Sciancalepore and colleagues, noted that while these applications are increasingly used, evidence regarding their effectiveness and classification remains fragmented.
The research team conducted a comprehensive search across major biomedical databases, including PubMed, Embase, and ISI Web of Science, up to January 7, 2026. The scope of the review was specifically focused on randomized controlled trials and non-randomized studies that assessed commercially available apps.
To provide a structured analysis of the interventions, the authors categorized the apps into three distinct groups: training, stimulation, and rehabilitation. This classification was applied using predefined criteria.
The review included sixty publications that referred to thirty different apps. A significant portion of these studies reported statistically significant improvements in cognitive scores, specifically using the Mini-Mental State Examination and the Montreal Cognitive Assessment. However, the authors emphasized that while these improvements were statistically significant, the effect sizes were generally small to moderate.
Methodological weaknesses emerged as a prominent theme in the findings. The review noted that sample size calculations were often absent. Furthermore, the clinical relevance of the observed improvements was inconsistently addressed across the studies.
The assessment of study quality revealed that most of the randomized controlled trials included in the review showed a high risk of bias. Quality of randomized controlled trials was assessed using the Cochrane Risk of Bias tool.
Another notable gap identified by the authors was the limited attention given to caregiver outcomes.
The authors concluded that while the digital cognitive-oriented therapies are promising, the current evidence is limited by these methodological weaknesses and the lack of a clear, harmonized regulatory framework. The review calls for more rigorous trials with clinically meaningful outcomes.
Subject of Research: Systematic review of commercially available apps for dementia and mild cognitive impairment
Article Title: Commercially available apps for the treatment of people living with dementia and mild cognitive impairment: a systematic review. What evidence and what urgencies from a public health perspective?
Article References: Sciancalepore, F., Ancidoni, A., Paggetti, A., Fabrizi, E., Morelli, S., Lacorte, E., Bacigalupo, I., Gatta, F. D., Simoni, M., Gasparini, M., Zanella, A., Stracciari, A., Marra, C., Caffarra, P., Gabelli, C., & Vanacore, N. (2026). Commercially available apps for the treatment of people living with dementia and mild cognitive impairment: a systematic review. What evidence and what urgencies from a public health perspective?. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-026-02206-1
Image Credits: AI Generated
DOI: 10.1186/s13195-026-02206-1
Keywords: dementia, mild cognitive impairment, digital health, systematic review, cognitive therapy, clinical trials, public health, Alzheimer's, Commercially, available, apps, treatment
News Source: Cassandra Pierce. (November 10, 2026). Systematic Review Finds Limited Evidence for Dementia Apps. Scienmag.



